A pre-clinical stage pharmaceutical company focused on bringing novel nucleic acid therapies to the market.
Founded in 2017, Solstar Pharma has built a precision RNAi platform that leverages years of research experience and unique insights into siRNA nucleic acid medicine.
Our siRNA platform technology is used to develop innovative anti-infective and anti-cancer agents to address the urgent need of new-generation antimicrobials, and novel anti-cancer compounds for aggressive cancers.
Solstar Pharma uses its breakthrough platform technologies to create new intellectual properties towards unmet medical needs.
LeadershipBoard of DirectorsScientific AdvisorsPartnerships
siRNA PlatformPipelineIntellectual Property SuiteScientific References